Medroxyprogesterone acetate alters the vaginal microbiota and microenvironment in women and increases susceptibility to HIV-1 in humanized mice

• Main Authors: Jocelyn M. Wessels (Author), Julie Lajoie (Author), Maeve I. J. Hay Cooper (Author), Kenneth Omollo (Author), Allison M. Felker (Author), Danielle Vitali (Author), Haley A. Dupont (Author), Philip V. Nguyen (Author), Kristen Mueller (Author), Fatemeh Vahedi (Author), Joshua Kimani (Author), Julius Oyugi (Author), Juliana Cheruiyot (Author), John N. Mungai (Author), Alexandre Deshiere (Author), Michel J. Tremblay (Author), Tony Mazzulli (Author), Jennifer C. Stearns (Author), Ali A. Ashkar (Author), Keith R. Fowke (Author), Michael G. Surette (Author), Charu Kaushic (Author)
• 格式: 圖書
• 出版: The Company of Biologists, 2019-10-01T00:00:00Z.
• 主題: article
• 在線閱讀: Connect to this object online.

The hormonal contraceptive medroxyprogesterone acetate (MPA) is associated with increased risk of human immunodeficiency virus (HIV), via incompletely understood mechanisms. Increased diversity in the vaginal microbiota modulates genital inflammation and is associated with increased HIV-1 acquisitio...